Studies conducted before clinical trials have indicated that a DNA vaccine (pTVG-AR) containing the ligand-binding domain of the androgen receptor (AR LBD) boosts CD8+ cells activization that target specific antigens, slows down the advancement of PCa and the development of castration-resistant disease, and extends the lifespan of mice with tumors. The gene discussed is AR; the disease is posterior cortical atrophy.